The stock gained 7.6% post-earnings, reflecting investor approval of revenue growth, margin expansion, and upward guidance. Strong execution on commercial integration and new market penetration appear to have outweighed any lingering skeptics.

• Q1 revenue reached $11.7 million, with gross margin expanding to 58%, supported by higher manufacturing volumes and ending revenue sharing with Ascensia.
• Raised 2026 full-year global net revenue guidance to $60–64 million, implying 70%–82% year-over-year growth.
• Commercial integration is progressing well, with full U.S. ownership of the Eversense commercial team and ongoing European integration.
• Direct-to-consumer new patient shipments grew nearly 100% year-over-year in Q1, accounting for ~60% of total new patient volume.
• Expansion of Eon Care network is driving scale, now performing over one-third of all Eversense insertions with presence in 34 states and plans to add more nurses.